{"id":26550,"date":"2025-07-28T03:38:10","date_gmt":"2025-07-28T03:38:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/26550\/"},"modified":"2025-07-28T03:38:10","modified_gmt":"2025-07-28T03:38:10","slug":"lilly-cuts-partnership-with-noom-in-latest-salvo-in-war-on-compounded-glp-1s","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/26550\/","title":{"rendered":"Lilly cuts partnership with Noom in latest salvo in war on compounded GLP-1s"},"content":{"rendered":"<p class=\"css-fiuwhu\"><a class=\"inline-stock css-1iix00n\" href=\"https:\/\/robinhood.com\/us\/en\/stocks\/LLY\/?source=sherwood\" rel=\"nofollow noopener\" target=\"_blank\">Eli Lilly<\/a> has terminated its partnership with Noom after the telehealth platform continued to sell knock-off versions of blockbuster GLP-1 drugs. <\/p>\n<p class=\"css-fiuwhu\">Lilly&#8217;s pharmacy provider &#8220;has notified Noom that it is terminating Noom\u2019s LillyDirect platform integration,&#8221; a spokesperson for the company told Sherwood News on Friday. The partnership with Noom <a href=\"https:\/\/www.noom.com\/in-the-news\/noom-to-streamline-access-to-zepbound-vials-with-noom-glp-1-companion-through-integration-with-lillydirect-pharmacy-provider\/?srsltid=AfmBOorBg0QPWgzglyyOX6ydk6Sc6pizfJQKR0M7EMT27BzxcPBQ5lpT\" target=\"_blank\" class=\"css-uubm0\" rel=\"noopener nofollow\">was announced<\/a> in March and allowed patients on the platform access to vials of Lilly&#8217;s blockbuster weight loss drug Zepbound, which are cheaper than the pens typically sold. <\/p>\n<p class=\"css-fiuwhu\">Noom has recently promoted &#8220;microdosed&#8221; GLP-1 treatments, using compounded versions of the diabetes and weight-loss medication. Lilly <a href=\"https:\/\/sherwood.news\/business\/eli-lillys-telehealth-deals-require-platforms-to-stop-compounding-glp-1s-cfo\/\" target=\"_blank\" class=\"css-uubm0\" rel=\"noopener nofollow\">has previously said<\/a> that part of its deals with telehealth partners are that they don&#8217;t continue selling knock-off versions of GLP-1s. <\/p>\n<p class=\"css-fiuwhu\">Noom did not immediately respond to a request for comment.<\/p>\n<p><img alt=\"Zepbound vial\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" decoding=\"async\" style=\"position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%\"\/><\/p>\n<p>Zepbound vials (Eli Lilly)<\/p>\n<p class=\"css-fiuwhu\">Telehealth companies like Hims &amp; Hers and Noom began selling copies of the popular weight-loss drugs while they were in shortage but were supposed to stop selling them at scale when supply issues waned earlier this year. <\/p>\n<p class=\"css-fiuwhu\">Lilly and Novo Nordisk, which makes rival weight-loss drugs, struck deals with several telehealth companies in what they described as an effort to transition patients who were on compounded versions of their drugs to the brand-name version. But some telehealth companies, which can make more money selling knock-offs compared shifting customers to the brand-name version, have quietly continued to offer compounded versions.<\/p>\n<p class=\"css-fiuwhu\">The end of Lilly&#8217;s partnership with Noom marks the latest schism between drugmakers who manufacture the massively popular drugs and the telehealth companies that have helped expand their reach.<\/p>\n<p class=\"css-fiuwhu\">Novo Nordisk has partnerships with telehealth partners. In June, Novo abruptly said it was calling off its deal with <a class=\"inline-stock css-1iix00n\" href=\"https:\/\/robinhood.com\/us\/en\/stocks\/HIMS\/?source=sherwood\" rel=\"nofollow noopener\" target=\"_blank\">Hims &amp; Hers<\/a> and accused the company of \u201c<a href=\"https:\/\/sherwood.news\/markets\/hims-and-hers-tanks-after-novo-nordisk-reportedly-ends-partnership\/\" target=\"_blank\" class=\"css-uubm0\" rel=\"noopener nofollow\">illegal mass compounding and deceptive marketing<\/a>.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly has terminated its partnership with Noom after the telehealth platform continued to sell knock-off versions of&hellip;\n","protected":false},"author":2,"featured_media":26551,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":["post-26550","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-health","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/26550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=26550"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/26550\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/26551"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=26550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=26550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=26550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}